Skip to main content
Equibles

Bruce Wendel

Board Member

ImmunityBio, Inc. (IBRX)

Chairman

GT Biopharma, Inc. (GTBP)

Equibles does not estimate personal net worth.

Get an email with a short summary when ImmunityBio, Inc. publishes a filing, an earnings call transcript or a press release.

Get IBRX alerts

About Bruce Wendel

Bruce Wendel is recorded as Board Member at ImmunityBio, Inc. (IBRX) and Chairman at GT Biopharma, Inc. (GTBP). The newest filing on record that lists Bruce Wendel as Board Member at ImmunityBio, Inc. (IBRX) is dated April 30, 2026. The newest filing on record that lists Bruce Wendel as Chairman at GT Biopharma, Inc. (GTBP) is dated April 29, 2024. ImmunityBio, Inc. reported in an 8-K filed December 15, 2025 that Bruce Wendel was appointed Board of Directors, effective December 12, 2025. GT Biopharma, Inc. reported in an 8-K filed May 13, 2025 that Bruce Wendel resigned as member of the Board and all committees thereof, effective May 7, 2025. GT Biopharma, Inc. is classified in the Biotechnology industry within the Healthcare sector. ImmunityBio, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at GT Biopharma, Inc. includes Anthony Cataldo (CEO), Dr. Gregory Berk (CEO), Michael Breen (CEO and Board Member) and 7 others.

“On December 10, 2025, the board of directors (the “Board”) of ImmunityBio, Inc. (the “Company”) appointed Bruce Wendel to the Board, effective as of December 12, 2025 (the “Effective Date”), with a term expiring at the Company’s 2026 annual meeting of stockholders.”
ImmunityBio, Inc. Form 8-K, filed December 15, 2025 · Read the filing
“On May 7, 2025, Bruce Wendel resigned as a member of the Board and all committees thereof.”
GT Biopharma, Inc. Form 8-K, filed May 13, 2025 · Read the filing

Affiliation history

Company network

Leadership on record at GT Biopharma, Inc.

Leadership on record at ImmunityBio, Inc.

Recent activity